Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)

Background: Hepatocellular carcinoma (HCC) (about 85 –90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese p eople.Summary: This guideline presents official recommendations of the National Health and Family Planning Commission of the People ’s Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China. The guideline was written by more than 50 experts in the field of HCC in China (including liver surgeons, medical oncologists, hepatologists, interventional radiologists, and diagnostic radiologi sts) on the basis of recent evidence and expert opinions, balance of benefits and harms, cost-benefit strategies, and other clinical considerations.Key Messages: The guideline presents the Chinese staging system, and recommendations regarding patients with HCC in China to ensure optimum patient outcomes.Liver Cancer
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research